Enliven Therapeutics, Inc (NASDAQ: ELVN) reported Q2 EPS of ($0.49), $0.06 better than the analyst estimate of ($0.55).

For earnings history and earnings-related data on Enliven Therapeutics, Inc (ELVN) click here.